Edwards Lifesciences Corporation (EW) - What Are Analysts Saying About This Stock?

Key Points

• Analysts are broadly bullish: Edwards Lifesciences has a “Moderate Buy” consensus, with 23 of 26 analysts rating it a buy and an average 12-month price target of $109.56. Recent firms raised targets, including UBS to $118 and Piper Sandler to $115.
• Quarterly results topped expectations: The company reported EPS of $0.80 versus estimates of $0.74, while revenue reached $1.72 billion and grew 10.5% year over year.
• Shares traded at $107.16, near their one-year high of $107.69. Insiders sold 53,945 shares worth about $5.5 million over the past 90 days.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and twenty-three have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $109.56.

A number of brokerages recently issued reports on EW. Mizuho set a $120.00 price objective on Edwards Lifesciences in a report on Thursday, November 5th. UBS Group upped their price target on Edwards Lifesciences from $110.00 to $118.00 and gave the company a "buy" rating in a research report on Thursday, November 5th. Wall Street Zen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Sunday, November 8th. Piper Sandler reissued an "overweight" rating and issued a $115.00 price target (up from $101.00) on shares of Edwards Lifesciences in a report on Thursday, November 5th. Finally, Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Thursday, November 5th.

Insider Activity at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company's stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $104.25, for a total transaction of $64,530.75. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $4,173,544.50. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,945 shares of company stock valued at $5,498,306 in the last ninety days. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. Entropy Technologies LP bought a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $5,204,000. Jump Financial LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $2,662,000. Flputnam Investment Management Co. lifted its holdings in shares of Edwards Lifesciences by 47.8% in the 3rd quarter. Flputnam Investment Management Co. now owns 7,437 shares of the medical research company's stock worth $642,000 after acquiring an additional 2,406 shares during the last quarter. L2 Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 4.2% in the 3rd quarter. L2 Asset Management LLC now owns 3,625 shares of the medical research company's stock valued at $313,000 after purchasing an additional 146 shares in the last quarter. Finally, Pathstone Holdings LLC boosted its stake in shares of Edwards Lifesciences by 0.3% in the 3rd quarter. Pathstone Holdings LLC now owns 86,688 shares of the medical research company's stock valued at $7,475,000 after purchasing an additional 257 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

EW traded up $1.36 during trading on Friday, hitting $107.16. 3,822,134 shares of the company traded hands, compared to its average volume of 4,833,862. The firm has a market cap of $61.62 billion, a P/E ratio of 60.54, a price-to-earnings-growth ratio of 2.82 and a beta of 0.85. The stock's fifty day moving average is $90.42 and its 200 day moving average is $86.32. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. Edwards Lifesciences has a one year low of $74.66 and a one year high of $107.69.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The business had revenue of $1.72 billion during the quarter, compared to the consensus estimate of $1.68 billion. During the same quarter last year, the company posted $0.67 earnings per share. The firm's quarterly revenue was up 10.5% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences will post 3.01 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.